author-photo

Noriko Togashi

Daiichi Sankyo

7

Papers

117

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells

2020 Oncotarget
Show All
- Source
- Cite
- Save
Citations (6)
Abstract 1318: Preclinical characterization of quizartinib and AC886, a metabolite of quizartinib, in AML models, and anti-leukemic activity of quizartinib on midostaurin-resistant AML cells

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

2019 Nature Communications
Show All
- Source
- Cite
- Save
Citations (56)
Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

2018 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Abstract B184: In vitro and in vivo profiling of novel mTORC1/2 inhibitor DS-3078a.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model.

2008 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (49)